Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Author： Zhao Liangli   Marshall Elaine   Kelland Lloyd   Baguley Bruce  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.25, Iss.3, 2007-06, pp. : 271-276

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Atwell G.J.   Yang S.   Denny W.A.  

European Journal of Medicinal Chemistry, Vol. 37, Iss. 10, 2002-10 ,pp. : 825-828

Elsevier

Access to resources Recommend Favorite

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

By Wang L.-C.   Ching Lai-Ming   Paxton James   Kestell Philip   Sutherland Rachel   Zhuang Li   Baguley Bruce  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 280-284

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)

By Jameson Michael B   Head Michelle  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 10, 2011-10 ,pp. : 1315-1326

Informa Healthcare

Access to resources Recommend Favorite

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

By Head Michelle   Jameson Michael B  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 295-304

Informa Healthcare

Access to resources Recommend Favorite

Pyridinylimidazole Based p38 MAP Kinase Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 2, Iss. 9, 2002-09 ,pp. : 1011-1020

Bentham Science Publishers

Access to resources Recommend Favorite